Due to a production error, there was a mistake in Table 2 as published. In Table 2, the asterisk mark (*), indicating *p < 0.05 compared with the placebo group (Dunnett's test), is incorrectly shown in the row “SWV with the knee fully flexed,” subcategory “Placebo,” and column “Change (Δ 24 weeks).” The corrected Table 2 appears below.
Table 2
| Variable | Group | Baseline | 12 weeks | 24 weeks | Change (Δ 12 weeks) | Change (Δ 24 weeks) | Two-way ANOVA (group × time) P-value |
|---|---|---|---|---|---|---|---|
| MRI measurements | |||||||
| Thigh muscle CSA (cm2) | Placebo | 98.7 ± 17.4 | 102.0 ± 18.5 | 104.2 ± 19.2 | 3.3 ± 2.6 | 5.5 ± 3.6 | 0.915 |
| Low-QG | 102.7 ± 25.4 | 106.2 ± 25.8 | 109.0 ± 28.2 | 3.4 ± 2.4 | 6.3 ± 4.4 | ||
| High-QG | 101.0 ± 25.3 | 105.1 ± 26.9 | 107.3 ± 27.4 | 4.1 ± 2.6 | 6.3 ± 4.5 | ||
| VL muscle CSA (cm2) | Placebo | 17.0 ± 3.6 | 17.6 ± 3.8 | 17.8 ± 3.9 | 0.6 ± 0.7 | 0.9 ± 0.9 | 0.635 |
| Low-QG | 18.3 ± 4.1 | 18.9 ± 4.2 | 19.5 ± 5.0 | 0.6 ± 0.8 | 1.2 ± 1.3 | ||
| High-QG | 17.7 ± 4.6 | 18.1 ± 4.6 | 18.5 ± 4.9 | 0.5 ± 0.7 | 0.8 ± 0.9 | ||
| DXA measurements | |||||||
| Leg lean mass (kg) | Placebo | 13.2 ± 2.3 | 13.5 ± 2.5 | 13.6 ± 2.7 | 0.3 ± 0.4 | 0.3 ± 0.6 | 0.332 |
| Low-QG | 13.7 ± 3.8 | 14.1 ± 3.9 | 13.9 ± 3.9 | 0.5 ± 0.4 | 0.2 ± 0.4 | ||
| High-QG | 13.1 ± 3.4 | 13.3 ± 3.6 | 13.4 ± 3.5 | 0.2 ± 0.5 | 0.3 ± 0.3 | ||
| Arm lean mass (kg) | Placebo | 4.1 ± 1.1 | 4.2 ± 1.1 | 4.2 ± 1.1 | 0.1 ± 0.1 | 0.0 ± 0.1 | 0.489 |
| Low-QG | 4.2 ± 1.4 | 4.2 ± 1.4 | 4.2 ± 1.4 | 0.0 ± 0.1 | 0.0 ± 0.2 | ||
| High-QG | 4.1 ± 1.3 | 4.1 ± 1.3 | 4.1 ± 1.2 | 0.1 ± 0.2 | 0.0 ± 0.1 | ||
| Whole-body lean mass (kg) | Placebo | 40.0 ± 6.9 | 40.7 ± 6.9 | 40.8 ± 7.3 | 0.6 ± 0.6 | 0.8 ± 0.9 | 0.904 |
| Low-QG | 40.6 ± 9.9 | 41.4 ± 10.1 | 41.4 ± 10.3 | 0.7 ± 0.7 | 0.8 ± 1.0 | ||
| High-QG | 39.8 ± 9.4 | 40.3 ± 9.4 | 40.6 ± 9.1 | 0.5 ± 0.6 | 0.8 ± 1.0 | ||
| SWE measurements of VL | |||||||
| SWV with the knee fully extended (m/s) | Placebo | 2.0 ± 0.1 | 2.0 ± 0.1 | 2.0 ± 0.1 | 0.0 ± 0.1 | 0.0 ± 0.1 | 0.452 |
| Low-QG | 1.9 ± 0.1 | 1.9 ± 0.2 | 1.9 ± 0.1 | 0.0 ± 0.2 | 0.0 ± 0.1 | ||
| High-QG | 2.0 ± 0.1 | 1.9 ± 0.2 | 2.0 ± 0.1 | 0.0 ± 0.1 | 0.0 ± 0.1 | ||
| SWV with the knee flexed at 90° (m/s) | Placebo | 3.0 ± 0.2 | 2.9 ± 0.2 | 2.8 ± 0.2 | −0.1 ± 0.2 | −0.2 ± 0.2 | 0.811 |
| Low-QG | 2.9 ± 0.2 | 2.8 ± 0.3 | 2.7 ± 0.1 | −0.1 ± 0.2 | −0.1 ± 0.2 | ||
| High-QG | 2.9 ± 0.3 | 2.8 ± 0.3 | 2.8 ± 0.2 | −0.2 ± 0.2 | −0.2 ± 0.2 | ||
| SWV with the knee fully flexed (m/s) | Placebo | 4.7 ± 0.6 | 4.6 ± 0.5 | 4.4 ± 0.4§§ | −0.1 ± 0.3 | −0.3 ± 0.4 | 0.023 |
| Low-QG | 5.0 ± 0.5 | 4.7 ± 0.6§§ | 4.4 ± 0.4§§ | −0.4 ± 0.3 | −0.6 ± 0.3* | ||
| High-QG | 5.0 ± 0.8 | 4.8 ± 0.8 | 4.4 ± 0.5§§ | −0.2 ± 0.5 | −0.6 ± 0.5* |
Effects of the intervention on muscle quantity and stiffness in the PPS analysis.
Values are expressed as means ± standard deviation. For the placebo (n = 16), low-QG (n = 16), and high-QG (n = 16) groups on MRI, DXA, and SWE measurements, where one set of SWE measurements in the placebo group at 12 weeks was missing because of no visit, there were no significant differences among the groups at baseline (one-way ANOVA). *p < 0.05 compared with placebo group (Dunnett's test). §§p < 0.01 compared with values at baseline (Dunnett's test). QG, quercetin glycoside; MRI, magnetic resonance imaging; CSA, cross-sectional area; VL, vastus lateralis; DXA, dual energy X-ray absorptiometry; SWE, shear wave elastography; and SWV, shear wave velocity.
The publisher apologizes for this mistake. The original article has been updated.
Summary
Keywords
muscle quality, shear wave elastography, passive muscle stiffness, whole-body lean mass, nutrition and exercise
Citation
Frontiers Production Office (2022) Erratum: Effects of quercetin glycoside supplementation combined with low-intensity resistance training on muscle quantity and stiffness: A randomized, controlled trial. Front. Nutr. 9:1028810. doi: 10.3389/fnut.2022.1028810
Received
26 August 2022
Accepted
26 August 2022
Published
27 September 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
9 - 2022
Updates
Copyright
© 2022 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office production.office@frontiersin.org
This article was submitted to Sport and Exercise Nutrition, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.